

Special Issue

Gene Therapy

Message from the Guest Editor

It is my great pleasure to introduce the Special Issue on “Gene Therapy”. In the 1990s, gene therapy was considered most promising and the perfect technology to develop medicines of the future. Today, an increasing number of clinical trials are in progress and several gene therapy-based drugs have been approved. It is therefore most appropriate to share the latest development with the scientific community in this special issue. As you will notice, the articles cover engineering of non-viral and viral vectors, gene therapy applications for various indications, such as cancer, hemophilia, AIDS, severe combined immunodeficiency and neurological diseases. Moreover immunotherapy, which has received a lot of attention recently, is presented in detail.

Guest Editor

Dr. Kenneth Lundstrom
PanTherapeutics, Rue des Remparts 4, CH1095 Lutry, Switzerland

Deadline for manuscript submissions

closed (31 August 2018)



Diseases

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/11825

Diseases
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diseases@mdpi.com

[mdpi.com/journal/
diseases](https://mdpi.com/journal/diseases)





Diseases

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
diseases](https://mdpi.com/journal/diseases)



About the Journal

Message from the Editor-in-Chief

Diseases is an international, peer-reviewed, open access, multidisciplinary journal that focuses on the latest outstanding research concerning diseases and conditions. Research articles, reviews, and other contents are released on the Internet immediately after acceptance. This journal aims to cover international conferences and symposia as new targets.

Diseases is increasingly gaining acceptance and visibility within scholars, and after only a few years of life, *Diseases* is now also covering specific topics with dedicated special issues. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Omar Cauli

Frailty and Cognitive Impairment—FROG Research Group, University of Valencia, 46010 Valencia, Spain

Author Benefits

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).